Krystal Biotech Rises 15.8% in a Month: Should You | U.S. Markets

Shares of Krystal Biotech KRYS have gained 15.8% up to now month in contrast with the industry’s growth of 4%. The stock has additionally outperformed the industry and the sector on this timeframe.

Final month, KRYS reported fourth-quarter 2024 outcomes. Whereas earnings beat estimates, gross sales missed the identical. Nonetheless, shares surged post the quarterly release, principally due to the robust uptake of Vyjuvek and inspiring pipeline progress.

KRYS Outperforms Business, Sector & S&P 500

Picture Supply: Zacks Funding Analysis

Robust Uptake of KRYS’ Vyjuvek  

In Could 2023, the FDA permitted Vyjuvek, the first-ever revocable gene remedy for treating sufferers aged six months or older with dystrophic epidermolysis bullosa (DEB).

DEB is a uncommon and extreme monogenic illness that impacts the pores and skin and mucosal tissues. It’s brought on by one or more mutations in a gene referred to as COL7A1.

Vyjuvek is a non-invasive, topical, redosable gene remedy designed to ship two copies of the COL7A1 gene when utilized on to DEB wounds.

Krystal recorded Vyjuvek gross sales of $290.5 million, up from $50.7 million in 2023.
It has made regular progress, securing entry and reimbursement for Vyjuvek since its launch in the USA.

As of February 2025, Krystal secured more than 510 reimbursement approvals for Vyjuvek in the USA and continues to take care of robust entry nationwide, together with constructive entry determinations for 97% of lives coated beneath industrial and Medicaid plans.

Krystal is trying to get Vyjuvek permitted in different geographies as properly.

The European Medicines Company’s (“EMA”) Committee for Medicinal Merchandise for Human Use has adopted a constructive opinion recommending the approval of Vyjuvek (beremagene geperpavec-svdt, or B-VEC) for the remedy of wounds in sufferers with DEB.

In October, Krystal Biotech filed a new drug software with Japan’s Prescription drugs and Medical Units Company. A call is predicted within the second half of 2025.

Krystal’s Makes Encouraging Pipeline Progress

The company can be advancing a strong preclinical and scientific pipeline of investigational genetic medicines within the fields of respiratory, oncology, dermatology, ophthalmology and aesthetics.

It’s evaluating KB407 for the remedy of cystic fibrosis. In December 2024, Krystal reported that single and repeat dosing of KB407 was secure and well-tolerated by sufferers in Cohorts 1 and a couple of of the continued CORAL-1 research.  Krystal expects to report interim molecular knowledge for Cohort 3 sufferers in mid-2025.

One other candidate, KB408, is being evaluated for the remedy of alpha-1 antitrypsin deficiency (AATD). In December, Krystal reported profitable SERPINA1 gene supply and useful alpha-1 antitrypsin expression reaching therapeutic ranges as half of an interim scientific replace for Cohorts 1 and a couple of of its ongoing 1 SERPENTINE-1 research. Inhaled KB408 was secure and well-tolerated at each examined dose ranges.

Consequently, based mostly on this promising initial knowledge, Krystal has concurrently expanded Cohort 2 and opened Cohort 3 of SERPENTINE-1 for more complete molecular assessments at each dose ranges and expects to report outcomes from the cohorts within the second half of 2025.

KB707 is being evaluated for the remedy of strong tumors of the lung.  Enrollment in KYANITE-1 is ongoing.

Enrollment is ongoing in OPAL-1, a part I/II open label, multi-center, dose escalation and growth research evaluating intratumoral KB707, both as monotherapy or together, in sufferers with domestically superior or metastatic strong tumor malignancies.

KB301 is being evaluated for the remedy of dynamic wrinkles of the décolleté. The company’s wholly-owned subsidiary, Jeune Aesthetics, beforehand introduced constructive interim security and efficacy outcomes from the PEARL-1 research of KB301 within the remedy of dynamic wrinkles of the décolleté. Based mostly on such knowledge, Jeune Aesthetics is at the moment gearing up to provoke a part II research of the candidate for a similar indication within the second half of 2025.

In November 2024, Jeune Aesthetics dosed the primary subject in an ongoing, randomized and placebo-controlled part I research PEARL-2 evaluating its second clinical-stage investigational aesthetic product KB304 for the remedy of wrinkles.

KRYS’s Valuation and Estimate Motion

Going by the price/gross sales ratio, KRYS’ shares at the moment trade at 10.58x ahead gross sales, decrease than its imply of 22.83x however larger than 1.63x for the drug industry.

Picture Supply: Zacks Funding Analysis

The Zacks Consensus Estimate for 2025 earnings per share (EPS) has elevated to $7.07 from $5.40 over the previous 30 days. The EPS estimate for 2025 has additionally elevated to $11.03 from $9.15 over the previous 30 days.

Picture Supply: Zacks Funding Analysis

Put money into KRYS Inventory

Massive biotech firms are usually thought-about secure havens for buyers on this sector. KRYS is a good stock to buy now, contemplating its good fundamentals and growth prospects.

The prospects for Krystal look robust as Vyjuvek is the primary FDA-approved gene remedy remedy for DEB. Approval in further geographies will additional enhance gross sales. The profitable development of different pipeline candidates ought to bode properly too.

With a money steadiness of $749.6 million as of Dec.  31, 2024, the company appears to be in a good place to develop its pipeline candidates.

Krystal’s Zacks Rank & Different Shares to Take into account

Krystal carries a Zacks Rank #2 (Purchase) at current.   

A pair of top-ranked shares within the biotech sector are Gilead Sciences GILD and BioMarin Pharmaceutical BMRN, every carrying a Zacks Rank #2 at current. You’ll be able to see the whole checklist of at present’s Zacks #1 Rank (Robust Purchase) shares right here.

Gilead Sciences

Up to now 30 days, Gilead Sciences’ EPS estimate for 2025 has elevated from $7.60 to $7.87. Throughout the identical timeframe, the determine for 2026 has elevated to $8.27 from $7.92.

GILD’s earnings beat estimates in every of the trailing 4 quarters, delivering an average shock of 19.47%.

BioMarin Pharmaceutical

Up to now 30 days, estimates for BioMarin Pharmaceutical’s 2025 EPS have elevated from $4.01 to $4.24. Estimate for 2026 EPS has elevated to $5.25 from $5.20 during the identical timeframe. BMRN’s earnings beat estimates in every of the trailing 4 quarters, delivering an average shock of 32.36%.
 

Zacks Names #1 Semiconductor Inventory

It is just one/9,000th the dimensions of NVIDIA which skyrocketed more than +800% since we really helpful it. NVIDIA continues to be robust, however our new prime chip stock has a lot more room to increase.

With robust earnings growth and an increasing buyer base, it is positioned to feed the rampant demand for Synthetic Intelligence, Machine Studying, and Web of Issues. International semiconductor manufacturing is projected to blow up from $452 billion in 2021 to $803 billion by 2028.

See This Inventory Now for Free >>

Need the latest suggestions from Zacks Funding Analysis? In the present day, you may obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report

BioMarin Pharmaceutical Inc. (BMRN) : Free Inventory Evaluation Report

Gilead Sciences, Inc. (GILD) : Free Inventory Evaluation Report

Krystal Biotech, Inc. (KRYS) : Free Inventory Evaluation Report

This text initially revealed on Zacks Funding Analysis (zacks.com).

Zacks Funding Analysis

The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.